Literature DB >> 26254712

Cardiac gene therapy: Recent advances and future directions.

Daniel Mason1, Yu-Zhe Chen1, Harini Venkata Krishnan1, Shilpa Sant2.   

Abstract

Gene therapy has the potential to serve as an adaptable platform technology for treating various diseases. Cardiovascular disease is a major cause of mortality in the developed world and genetic modification is steadily becoming a more plausible method to repair and regenerate heart tissue. Recently, new gene targets to treat cardiovascular disease have been identified and developed into therapies that have shown promise in animal models. Some of these therapies have advanced to clinical testing. Despite these recent successes, several barriers must be overcome for gene therapy to become a widely used treatment of cardiovascular diseases. In this review, we evaluate specific genetic targets that can be exploited to treat cardiovascular diseases, list the important delivery barriers for the gene carriers, assess the most promising methods of delivering the genetic information, and discuss the current status of clinical trials involving gene therapies targeted to the heart.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cardiovascular gene therapy; Non-viral carriers; Viral carriers

Mesh:

Year:  2015        PMID: 26254712     DOI: 10.1016/j.jconrel.2015.08.001

Source DB:  PubMed          Journal:  J Control Release        ISSN: 0168-3659            Impact factor:   9.776


  9 in total

Review 1.  Drug discovery and development for rare genetic disorders.

Authors:  Wei Sun; Wei Zheng; Anton Simeonov
Journal:  Am J Med Genet A       Date:  2017-07-21       Impact factor: 2.802

Review 2.  Cardiac gene therapy: are we there yet?

Authors:  P N Matkar; H Leong-Poi; K K Singh
Journal:  Gene Ther       Date:  2016-04-29       Impact factor: 5.250

3.  Ionizable Lipid Nanoparticle-Mediated Delivery of Plasmid DNA in Cardiomyocytes.

Authors:  Sérgio Scalzo; Anderson K Santos; Heloísa A S Ferreira; Pedro A Costa; Pedro H D M Prazeres; Natália J A da Silva; Lays C Guimarães; Mário de Morais E Silva; Marco T R Rodrigues Alves; Celso T R Viana; Itamar C G Jesus; Alice P Rodrigues; Alexander Birbrair; Anderson O Lobo; Frederic Frezard; Michael J Mitchell; Silvia Guatimosim; Pedro Pires Goulart Guimaraes
Journal:  Int J Nanomedicine       Date:  2022-06-30

Review 4.  Hypoxic tumor microenvironment: Opportunities to develop targeted therapies.

Authors:  Akhil Patel; Shilpa Sant
Journal:  Biotechnol Adv       Date:  2016-04-30       Impact factor: 14.227

5.  Shape-Specific Nanoceria Mitigate Oxidative Stress-Induced Calcification in Primary Human Valvular Interstitial Cell Culture.

Authors:  Yingfei Xue; Cynthia St Hilaire; Luis Hortells; Julie A Phillippi; Vinayak Sant; Shilpa Sant
Journal:  Cell Mol Bioeng       Date:  2017-07-25       Impact factor: 2.321

6.  MicroRNA-24 Attenuates Neointimal Hyperplasia in the Diabetic Rat Carotid Artery Injury Model by Inhibiting Wnt4 Signaling Pathway.

Authors:  Jian Yang; Zhixing Fan; Jun Yang; Jiawang Ding; Chaojun Yang; Lihua Chen
Journal:  Int J Mol Sci       Date:  2016-05-24       Impact factor: 5.923

Review 7.  Recent Progress in Stem Cell Modification for Cardiac Regeneration.

Authors:  Heiko Lemcke; Natalia Voronina; Gustav Steinhoff; Robert David
Journal:  Stem Cells Int       Date:  2018-01-16       Impact factor: 5.443

8.  RP105 alleviates myocardial ischemia reperfusion injury via inhibiting TLR4/TRIF signaling pathways.

Authors:  Jun Yang; Chaojun Yang; Jian Yang; Jiawang Ding; Xinxin Li; Qinqin Yu; Xin Guo; Zhixing Fan; Huibo Wang
Journal:  Int J Mol Med       Date:  2018-03-06       Impact factor: 4.101

Review 9.  Nanotechnology in cardiac stem cell therapy: cell modulation, imaging and gene delivery.

Authors:  Elangovan Sarathkumar; Marina Victor; Jaivardhan A Menon; Kunnumpurathu Jibin; Suresh Padmini; Ramapurath S Jayasree
Journal:  RSC Adv       Date:  2021-10-26       Impact factor: 4.036

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.